PT-141

• Week 1-2: Effects usually start in 45-60 min; nausea most likely now
• Week 2-4: Nausea usually eases; notice changes in desire
• Week 4-8: Judge it; label says stop if no help by week 8
• Week 8-12: If it helps: max 1 dose a day, 8 a month; watch dark patches
• Side effects: Often nausea or flushing; get help for chest pain or fainting

More on each stage

Week 1-2

Your first doses. Effects usually start 45 to 60 minutes after the shot and, by community reports, last 6 to 12 hours. Nausea is most likely now: in the approval trials 21 in 100 women had nausea after their first dose. It began within about an hour and lasted about 2 hours. Flushing (a warm, red face) is also common.

Week 2-4

Nausea usually eases once you are past your first dose: in the trials it fell from 21 in 100 after the first dose to about 3 in 100 after later doses. Notice whether desire, arousal, or interest in sex picks up on the days you dose. If 500 mcg did too little and you felt fine, try 1 mg next time.

Week 4-8

Judge whether it is working. Count how often you used it and whether desire and enjoyment improved. The FDA label says to stop if there is no improvement after 8 weeks.

Week 8-12

If it helps, keep using it as needed within the limits (one dose a day, 8 a month). For the longer term, a 52-week open-label follow-up enrolled 684 women from the main trials: those who kept using it kept their gains in desire through the year, and no new safety problems appeared. Watch for any new dark patches on your skin or gums.

Side effects

Most often nausea, flushing, headache, and a sore spot where you inject. Blood pressure rises a little for a few hours after each dose. Stop and get help right away for chest pain, a severe headache, fainting, or trouble breathing.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• More sexual desire, less distress (women)

  FDA-labeled

  In two 24-week trials of 1,247 premenopausal women with low sexual desire, 1.75 mg as needed raised desire scores and lowered distress about low desire, compared with placebo.12

• Gains that held for a year

  Clinical trial

  Women who kept using it in a 52-week open-label follow-up kept their gains in desire and lower distress, and no new safety problems appeared.3

• More satisfying sex (women)

  Clinical trial

  In a 12-week trial with results from 327 women, the 1.25 and 1.75 mg doses, taken together, added about 0.7 satisfying sexual events a month, against 0.2 on placebo, and improved sexual function scores.4

• Erections in men, including some Viagra non-responders

  Human study

  In small early studies, single shots above 1 mg caused erections in healthy men. Shots of 4 or 6 mg worked in men who had a poor response to 100 mg Viagra. The FDA has not approved it for men.58

• Works on desire itself

  Animal/lab study

  In female rats, PT-141 increased behaviours that signal wanting sex without changing other sexual reflexes or general activity. The researchers concluded that the brain's melanocortin system helps control female desire, which is why PT-141 is studied as a desire drug.910

• Stronger desire, men and women

  Community report

  Community users report strong desire in both men and women, a different feeling from erection pills. Men report better erections, mainly when they also take sildenafil or tadalafil. Many start at 0.5 to 1 mg to keep nausea down.12

What it has been studied for

• Low sexual desire that causes distress in premenopausal women (hypoactive sexual desire disorder, HSDD). This is the only approved use.12FDA-labeled
• Female sexual dysfunction, including low desire and low arousal, in premenopausal women4Clinical trial
• Erectile dysfunction in men, including men who did not respond well to Viagra (small early studies; not approved for men)56Human study
• Erectile dysfunction, combined with a low dose of sildenafil (Viagra), in 19 men7Human study
• Sexual desire behaviour in female rats910Animal/lab study

PT-141 (bremelanotide) is a lab-made ring of 7 building blocks (amino acids), based on a natural body hormone. It turns on two kinds of locks on cells: one mainly in the brain, the other on the skin's pigment cells. The FDA label says nobody knows exactly how it boosts desire. In rats, it switches on the hypothalamus, a brain area that controls sexual behaviour. It may work by releasing dopamine, a brain messenger, there. Turning on the skin's pigment lock explains the dark patches some people get.

Peak

About 1 hour after a shot under the skin (range 30 minutes to 1 hour). Nearly all of the dose reaches the blood. Belly and thigh give the same levels.

Half-life

About 2.7 hours on average (range 1.9 to 4 hours) after a shot under the skin. The label says how long each dose works is not known.

Cleared

The body breaks it down by cutting the peptide apart. In a study with a tagged dose, about 65% turned up in urine and 23% in stool. Blood pressure and heart rate usually return to normal within 12 hours. The label does not say how many hours it takes to clear a dose. In severe kidney disease, total exposure (the amount in the blood over time) was about 2 times higher.

Half-life is how long it takes the body to remove half of a dose.1

Only when you need it. Never more than one dose in 24 hours. 45 to 60 minutes before sex. The FDA label says at least 45 minutes before. No more than 8 doses a month. In the approval trials most women used it 2 to 3 times a month, and no more than once a week. Units are for a 10 mg vial mixed with 1 mL water (10 mg per mL).

Step-up plan

When	Dose	Units
First dose Start here Store dose	500 mcg	5 units
Later doses, only if 500 mcg did too little and you felt fine	1 mg	10 units
Most per dose (the FDA-approved dose)	1.75 mg	17.5 units

• Lower end · off-label male + PDE5 stack

  1.0-2.0 mg (off-label, often with a PDE5 inhibitor)

  The off-label male protocol biohackers discuss most, frequently stacked with sildenafil or tadalafil — a combination with some clinical-trial support.12

• Most common · lower-dose; curbs nausea

  0.5-1.0 mg, on-demand

  The community-derived lower dose many landed on to curb the nausea that hits roughly 40% of users at the full 1.75 mg label dose — reported as still effective for libido and arousal.12

• Higher end · FDA-labeled ceiling

  1.75 mg, on-demand

  The FDA-labeled Vyleesi dose (1.75 mg) that the community treats as the ceiling, capped at 8 doses per month — most biohackers stay below it to limit nausea.12

• Low-dose injection

  0.5 to 1 mg under the skin, about 60 minutes before sex, with the same limits as the label (one dose a day, 8 a month). Chosen to cut nausea. The store dose of 500 mcg (5 units) is the starting point.12

• Men

  1 to 2 mg under the skin, 1 to 2 hours before sex, often with sildenafil or tadalafil. Doses above 1.75 mg go past the FDA dose and raise the risk of nausea and blood pressure effects.121

Research protocols

• FDA label (Vyleesi, premenopausal women)

  1.75 mg under the skin of the belly or thigh, as needed, at least 45 minutes before sex. No more than one dose in 24 hours and no more than 8 doses a month. Stop after 8 weeks if there is no improvement. With this vial's mix, 1.75 mg is 17.5 units.1

• Phase 3 trials (RECONNECT, 1,247 women, 24 weeks)

  1.75 mg as needed, about 45 minutes before sex, no more than once a day and up to 12 doses in each 4-week period. Most women used it 2 to 3 times a month; the typical woman used 10 doses in 24 weeks.12

• Dose-finding trial (397 women, results from 327, 12 weeks)

  0.75, 1.25, or 1.75 mg under the skin about 45 minutes before sex, no more than once a day and no more than 16 doses in 4 weeks. The 1.25 and 1.75 mg doses, taken together, beat placebo.4

• Men, single shots in a lab (early study)

  Healthy men got one shot of 0.3 to 10 mg; doses above 1 mg caused erections. Men with a poor Viagra response got 4 or 6 mg, and both worked. These were one-time lab doses, much higher than the FDA dose.5

• Men, nasal spray (early study)

  Nasal doses above 7 mg caused erections, starting about 30 minutes after the dose. Nasal and injected doses are not the same strength and cannot be swapped.6

PT-141 (bremelanotide / Vyleesi) is FDA-approved only for premenopausal HSDD — male use for ED is entirely off-label. Nausea affects ~40% at the labeled dose. Blood-pressure changes can occur; it is not recommended for uncontrolled hypertension or cardiovascular disease.

Dosing guidance built from the cited research and community reports. It is not a prescription.

On

As needed, up to 8 a month, 24 h apart

Break

Stop if no help after 8 weeks

Why the break helps

PT-141 is not taken daily, so there is no on-off cycle. The limits protect you. Each dose raises blood pressure for a few hours, and doses close together may stack that effect. Dark patches on the skin (including the face, gums, and breasts) were far more common with daily use: 38 in 100 people had them after 8 daily doses, compared with 1 in 100 at up to 8 doses a month. People with darker skin were more likely to get them. It was not confirmed that the patches faded in everyone after stopping, and the label warns they may not go away. The 8-week check stops you from taking side effects for no benefit.

Common

• Nausea (40 in 100 women in the trials at 1.75 mg), worst with the first dose. It starts within about an hour and lasts about 2 hours. Vomiting happened in about 5 in 100.

  What to do Stay at 500 mcg, or go back to it. Lie down and sip water. Nausea is much less common after the first dose. Taking ondansetron (an anti-nausea pill) 30 minutes before did not prevent it in a study. If nausea stays severe, stop.

• Flushing: a warm, red face (about 20 in 100)

  What to do In the trials no flushing was serious and few cases were severe. Stop only if it bothers you.

• Headache (about 11 in 100)

  What to do Drink water and rest; a regular pain reliever usually helps. Get help if it is severe or will not go away.

• Redness, pain, itching, or a bruise where you inject (about 13 in 100)

  What to do Rotate sites each time. If the redness spreads or the spot gets hot, see the infection warning below.

• A small rise in blood pressure and a slower pulse for a few hours after each dose

  What to do If you own a blood pressure cuff, check it a few hours after your first dose. Never take more than one dose in 24 hours.

Stop and get help

• Chest pain, shortness of breath, fainting, a sudden severe headache, weakness on one side, or trouble speaking

  What to do Call 911 (or your local emergency number) right away. Do not take PT-141 again until a doctor clears you.

• New dark patches on the face, gums, or breasts (more likely with darker skin or frequent doses)

  What to do Stop PT-141 and show a doctor. The label warns the patches may not go away, even after you stop.

• Yellow skin or eyes, dark urine, or pain in the upper right belly (one case of liver inflammation was reported in the trials)

  What to do Stop PT-141 and see a doctor the same day.

• Allergic reaction: swelling of the face, lips, or throat, trouble breathing, or a widespread rash

  What to do Call 911 right away. Do not take it again.

• Infection where you inject: redness that spreads, heat, pus, red streaks, or fever

  What to do Stop injecting and see a doctor the same day.

Do not use if

• You have high blood pressure that is not under control, or any known heart or blood vessel disease (the FDA label says not to use it).
• You are at high risk for heart disease (the FDA label does not recommend it).
• You are pregnant or could become pregnant without using birth control. Animal studies showed harm to unborn young, and the label says to use effective birth control and stop if you might be pregnant.
• You are breastfeeding. No one knows whether it passes into breast milk.
• You take naltrexone pills for alcohol or opioid addiction.
• You have severe kidney or liver disease, unless a doctor says otherwise. Side effects such as nausea may be stronger.
• You are under 18.

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), away from heat and light. Do not freeze it.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.5 mL (50-unit) U-100 insulin syringe.

1. With this mix, every 1 unit line on a U-100 insulin syringe holds 100 mcg. Draw to 5 units for 500 mcg, 10 units for 1 mg, or 17.5 units for 1.75 mg.
2. Online guides often assume a different amount of water. Their unit numbers will not match this mix. Always go by the units on this page.
3. Hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
4. Pinch a fold of skin, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out.
5. Nausea is worst with the first dose. Take your first dose on a quiet day at home, so you learn how your body reacts before it matters.
6. Check the liquid before each draw. Do not use it if it is cloudy, has changed colour, or has bits floating in it.
7. Use a new sterile syringe every time and never share one.

• Oxytocin

  Community users pair them as an "intimacy stack": oxytocin for closeness and bonding, PT-141 for desire. At least one clinic sells a pill that combines the two with Cialis. In a study of 29 couples, oxytocin made orgasm a bit stronger and raised contentment afterwards.131411

Interactions

• Blood pressure: high blood pressure, heart disease, or stimulants that raise blood pressure

  Each dose raises blood pressure for a few hours. The label forbids it with uncontrolled high blood pressure or known heart disease.

  What to do Make sure your blood pressure is under control before you start, and ask your doctor if you have any heart condition.

• Sildenafil (Viagra), tadalafil (Cialis), and other erection pills

  In 19 men, a low dose of PT-141 (nasal) plus 25 mg sildenafil gave stronger erections than sildenafil alone, with no new side effects. These pills lower blood pressure while PT-141 raises it; the combined effect has not been studied in a larger group.

  What to do Ask your doctor before combining. Never take these pills with nitrate heart medicines such as nitroglycerin.

• Naltrexone pills (for alcohol or opioid addiction)

  PT-141 can sharply lower the amount of naltrexone that reaches your blood, so the addiction treatment may fail.

  What to do Do not use PT-141 while taking naltrexone pills.

• Other pills, especially antibiotics and fast-acting pain pills (such as indomethacin)

  PT-141 may slow stomach emptying, so pills taken around the same time may be absorbed more slowly and work less well.

  What to do Do not use PT-141 while on a course of antibiotics. If a pain pill seems slow to work, that may be why.

• Alcohol

  Alcohol did not change PT-141 levels in a study, but headache was more common with the two together than with PT-141 alone.

  What to do Keep drinking light on dosing days.

Videos

• PT-141: Hype or Legit Libido Fix?
• A Comprehensive Guide to Treating Sexual Dysfunction (includes PT-141)

Sources

1. 1Vyleesi (bremelanotide) FDA prescribing information, revised March 2024 (DailyMed listing updated November 2025)Drug label
2. 2Kingsberg et al., Obstet Gynecol 2019: two Phase 3 trials of bremelanotide (RECONNECT)Clinical trial
3. 3Simon et al., Obstet Gynecol 2019: long-term safety and efficacy of bremelanotide (52-week extension)Clinical trial
4. 4Clayton et al., Womens Health 2016: bremelanotide dose-finding trial in premenopausal womenClinical trial
5. 5Rosen et al., Int J Impot Res 2004: PT-141 injected under the skin in healthy men and Viagra non-respondersStudy
6. 6Diamond et al., Int J Impot Res 2004: nasal PT-141 in healthy men and men with erectile dysfunctionStudy
7. 7Diamond et al., Urology 2005: low-dose nasal PT-141 plus sildenafil in men with erectile dysfunctionStudy
8. 8Molinoff et al., Ann N Y Acad Sci 2003: PT-141, a melanocortin agonist for sexual dysfunctionReview
9. 9Pfaus et al., PNAS 2004: PT-141 selectively increases sexual solicitation in female ratsStudy
10. 10Pfaus et al., J Sex Med 2007: bremelanotide's brain effects on female sexual function (review)Review
11. 11Behnia et al., Horm Behav 2014: nasal oxytocin and sexual experience in couplesStudy
12. 12Peptide Protocol Wiki: PT-141 community protocols (150 reports)Community
13. 13Peptide Protocol Wiki: oxytocin community protocols (Oxytocin + PT-141 intimacy stack)Community
14. 14The San Francisco Standard, August 2026: clinics and users combining PT-141 with oxytocinReference

Where people discuss it

• r/Peptides (subreddit)
• Peptide Protocol Wiki — PT-141 community (150 reports)

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented